FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891623007> ?p ?o ?g. }

• W2891623007 endingPage "1018" @default.
• W2891623007 startingPage "1004" @default.
• W2891623007 abstract "Multiple studies have shown seemingly unfavorable changes in lipid profiles associated with interleukin-6 receptor (IL-6R) antagonists and some other therapies for rheumatoid arthritis. The aim of this study was to assess the real-world cardiovascular disease (CVD) risk associated with tocilizumab, the first anti-IL-6R medication approved for the treatment of RA.We conducted a cohort study using 2006-2015 Medicare and MarketScan claims for patients with RA in whom treatment with biologic disease-modifying antirheumatic drugs was initiated after January 1, 2010. The primary outcome was a composite of myocardial infarction, stroke, and fatal CVD, assessed using a validated method. The influence of potential confounding due to RA disease activity was assessed in a subgroup analysis (~5-10% of biologic therapy initiations) using the multi-biomarker disease activity (MBDA) score.A total of 88,463 patients with RA were included. The crude incidence rate (IR) per 1,000 patient-years for composite CVD events among Medicare patients ranged from 11.8 (95% confidence interval [95% CI] 9.7-14.4) for etanercept users to 17.3 (95% CI 15.2-19.7) for infliximab users. The crude IR for pooled users of a tumor necrosis factor inhibitor was 15.0 (95% CI 13.9-16.3). Compared to tocilizumab, the corresponding adjusted hazard ratios (HRs) were 1.01 (95% CI 0.79-1.28) for abatacept, 1.16 (95% CI 0.89-1.53) for rituximab, 1.10 (95% CI 0.80-1.51) for etanercept, 1.33 (95% CI 0.99-1.80) for adalimumab, and 1.61 (95% CI 1.22-2.12) for infliximab. There were no statistically significant differences in the risk of CVD between tocilizumab and any other biologic when MarketScan data were used. Results were robust in numerous subgroup analyses and after external adjustment to control for RA disease activity in the subgroup of patients with linked MBDA test results (n = 4,156).Tocilizumab was associated with a CVD risk comparable to that for etanercept as well as a number of other biologics used for the treatment of RA." @default.
• W2891623007 created "2018-09-27" @default.
• W2891623007 creator A5000754711 @default.
• W2891623007 creator A5043053903 @default.
• W2891623007 creator A5070022403 @default.
• W2891623007 creator A5075536702 @default.
• W2891623007 creator A5079959622 @default.
• W2891623007 date "2019-08-01" @default.
• W2891623007 modified "2023-10-12" @default.
• W2891623007 title "Tocilizumab and the Risk of Cardiovascular Disease: Direct Comparison Among Biologic Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis Patients." @default.
• W2891623007 cites W1958271975 @default.
• W2891623007 cites W1967820629 @default.
• W2891623007 cites W1993160453 @default.
• W2891623007 cites W2015410646 @default.
• W2891623007 cites W2032091500 @default.
• W2891623007 cites W2034948055 @default.
• W2891623007 cites W2063236332 @default.
• W2891623007 cites W2067504868 @default.
• W2891623007 cites W2074639523 @default.
• W2891623007 cites W2075619622 @default.
• W2891623007 cites W2076859422 @default.
• W2891623007 cites W2082081076 @default.
• W2891623007 cites W2125212735 @default.
• W2891623007 cites W2157399320 @default.
• W2891623007 cites W2159033141 @default.
• W2891623007 cites W2171624524 @default.
• W2891623007 cites W2179100316 @default.
• W2891623007 cites W2279146469 @default.
• W2891623007 cites W2316376271 @default.
• W2891623007 cites W2336100848 @default.
• W2891623007 cites W2548897914 @default.
• W2891623007 cites W2591643981 @default.
• W2891623007 cites W2779485274 @default.
• W2891623007 cites W2790487921 @default.
• W2891623007 cites W4232411700 @default.
• W2891623007 doi "https://doi.org/10.1002/acr.23737" @default.
• W2891623007 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30175897" @default.
• W2891623007 hasPublicationYear "2019" @default.
• W2891623007 type Work @default.
• W2891623007 sameAs 2891623007 @default.
• W2891623007 citedByCount "45" @default.
• W2891623007 countsByYear W28916230072018 @default.
• W2891623007 countsByYear W28916230072019 @default.
• W2891623007 countsByYear W28916230072020 @default.
• W2891623007 countsByYear W28916230072021 @default.
• W2891623007 countsByYear W28916230072022 @default.
• W2891623007 countsByYear W28916230072023 @default.
• W2891623007 crossrefType "journal-article" @default.
• W2891623007 hasAuthorship W2891623007A5000754711 @default.
• W2891623007 hasAuthorship W2891623007A5043053903 @default.
• W2891623007 hasAuthorship W2891623007A5070022403 @default.
• W2891623007 hasAuthorship W2891623007A5075536702 @default.
• W2891623007 hasAuthorship W2891623007A5079959622 @default.
• W2891623007 hasBestOaLocation W28916230071 @default.
• W2891623007 hasConcept C126322002 @default.
• W2891623007 hasConcept C207103383 @default.
• W2891623007 hasConcept C2777138892 @default.
• W2891623007 hasConcept C2777178219 @default.
• W2891623007 hasConcept C2777226972 @default.
• W2891623007 hasConcept C2777575956 @default.
• W2891623007 hasConcept C2779134260 @default.
• W2891623007 hasConcept C2779338263 @default.
• W2891623007 hasConcept C2779605438 @default.
• W2891623007 hasConcept C2780132546 @default.
• W2891623007 hasConcept C2780653079 @default.
• W2891623007 hasConcept C2781290027 @default.
• W2891623007 hasConcept C44249647 @default.
• W2891623007 hasConcept C71924100 @default.
• W2891623007 hasConceptScore W2891623007C126322002 @default.
• W2891623007 hasConceptScore W2891623007C207103383 @default.
• W2891623007 hasConceptScore W2891623007C2777138892 @default.
• W2891623007 hasConceptScore W2891623007C2777178219 @default.
• W2891623007 hasConceptScore W2891623007C2777226972 @default.
• W2891623007 hasConceptScore W2891623007C2777575956 @default.
• W2891623007 hasConceptScore W2891623007C2779134260 @default.
• W2891623007 hasConceptScore W2891623007C2779338263 @default.
• W2891623007 hasConceptScore W2891623007C2779605438 @default.
• W2891623007 hasConceptScore W2891623007C2780132546 @default.
• W2891623007 hasConceptScore W2891623007C2780653079 @default.
• W2891623007 hasConceptScore W2891623007C2781290027 @default.
• W2891623007 hasConceptScore W2891623007C44249647 @default.
• W2891623007 hasConceptScore W2891623007C71924100 @default.
• W2891623007 hasFunder F4320308927 @default.
• W2891623007 hasIssue "8" @default.
• W2891623007 hasLocation W28916230071 @default.
• W2891623007 hasLocation W28916230072 @default.
• W2891623007 hasOpenAccess W2891623007 @default.
• W2891623007 hasPrimaryLocation W28916230071 @default.
• W2891623007 hasRelatedWork W1973584386 @default.
• W2891623007 hasRelatedWork W2119512053 @default.
• W2891623007 hasRelatedWork W2139415330 @default.
• W2891623007 hasRelatedWork W2143724376 @default.
• W2891623007 hasRelatedWork W2289989023 @default.
• W2891623007 hasRelatedWork W2315852881 @default.
• W2891623007 hasRelatedWork W2327327957 @default.
• W2891623007 hasRelatedWork W2910972412 @default.
• W2891623007 hasRelatedWork W4200216825 @default.
• W2891623007 hasRelatedWork W4206752617 @default.

• next